Srinagar Observer
Wednesday, June 4, 2025
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial

    The Habitual Shifts

    Assuring Crime Free Society

    Stimulating Young Energy

    An Ethical Denial

    Beating Inflation

    The Timely Exigence

    Extension in Academics

     Aiding Healthcare

    Development in Disguise

    Gender-Free Conviction

  • Edit-Oped
  • ePaper
No Result
View All Result
Srinagar Observer
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial

    The Habitual Shifts

    Assuring Crime Free Society

    Stimulating Young Energy

    An Ethical Denial

    Beating Inflation

    The Timely Exigence

    Extension in Academics

     Aiding Healthcare

    Development in Disguise

    Gender-Free Conviction

  • Edit-Oped
  • ePaper
No Result
View All Result
Srinagar Observer
No Result
View All Result
Home National

NATCO receives final approval for Everolimus tablets for US market

SO NEWS Desk by SO NEWS Desk
March 8, 2021
in National
A A
0
Share on FacebookShare on TwitterWhatsApp

Mumbai: Pharma major, Natco Pharma said that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received final approval for its Abbreviated New Drug Application (ANDA) for Everolimus Tablets (generic for Afinitor) from the US Food and Drug Administration (USFDA).

NATCO’s partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks, company said in a filing with BSE.

RELATED POSTS

Leaders slam Kharge over remarks on Operation Sindoor

Delhi: CBI arrests IRS officer, aide in bribery case

The launch of 10mg strength of the product is subject to confidential terms of a settlement and license agreement entered into with the owner of the Afinitor brand. The launch date of 10mg strength of the product will be announced at a later date.

The above strengths of Everolimus are indicated in the treatment of breast cancer and a few other types of cancers. As per industry sales data, Afinitor and its therapeutic equivalents had generated annual sales of USD712 million in USA during the twelve months ending December 2020.

Related

ShareTweetSend
SO NEWS Desk

SO NEWS Desk

Related Posts

Leaders slam Kharge over remarks on Operation Sindoor

by SO NEWS Desk
June 1, 2025
0

New Delhi, June 1 - Congress President Mallikarjun Kharge’s remarks on Operation Sindoor and India’s defence preparedness have sparked a...

Delhi: CBI arrests IRS officer, aide in bribery case

by SO NEWS Desk
June 1, 2025
0

New Delhi, June 1 - The Central Bureau of Investigation (CBI) has arrested two persons, including a senior Indian Revenue...

If Rahul Gandhi contests elections from Pak, he will win with a thumping majority: Acharya Pramod Krishnam

by SO NEWS Desk
May 31, 2025
0

Ghaziabad, May 31 - Spiritual guru Acharya Pramod Krishnam on Saturday launched a sharp attack on Leader of the Opposition...

Children, women among seven killed in Arunachal landslides

by SO NEWS Desk
May 31, 2025
0

Itanagar, May 31 - Seven people, including two women and two children, were killed in a massive landslide on National...

Delhi BJP Chief lauds CM Rekha Gupta’s 100-day performance

by SO NEWS Desk
May 30, 2025
0

New Delhi, May 30 - Delhi BJP President Virendraa Sachdeva, on Friday, lauded the performance of Chief Minister Rekha Gupta's...

Next Post

Pakistani wives of former Kashmiri militants, addressed a press conference in Srinagar on Monday.

1993 blast convict Noor Khan dies

Digital Edition

Srinagar Observer

Srinagar Observer is an English Newspaper based in Jammu and Kashmir

CATEGORY

  • Business
  • Edit-Oped
  • Editorial
  • Jammu
  • Kashmir
  • Latest
  • National
  • Photo Gallery
  • Sports
  • Top News
  • Uncategorized
  • World

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 9,375 other subscribers

Archives

No Result
View All Result
  • Home
  • About Us
  • Contact Us
  • Advertise

© 2024 Srinagar Observer - Designed by GITS.

No Result
View All Result
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial
  • Edit-Oped
  • ePaper

© 2024 Srinagar Observer - Designed by GITS.